PubMed · 3261180
Decrease in BSF-2/IL-6 response in advanced cases of multiple myeloma.
Abstract
Human myeloma cells freshly isolated from 40 patients with IgG multiple myeloma (MM, 10 in stage I and 30 in stage III), were cultured for 48 hours with recombinant B cell stimulatory factor 2 (rBSF-2)/interleukin-6 (IL-6), which is considered a major growth factor for myeloma cells. Uptake of 3H-thymidine by these purified myeloma cells was measured, and BSF-2 response was evaluated by stimulation index and delta cpm induced by rBSF-2. Myeloma cells from cases in stage I responded to rBSF-2 better than those in stage III. Moreover rBSF-2 responders also showed better response to chemotherapy. Therefore, these results suggest that in vitro response of myeloma cells to BSF-2 correlates with disease progression and clinical response in patients of MM.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
H Asaoku, M Kawano, K Iwato, O Tanabe, H Tanaka, T Hirano, T Kishimoto, A Kuramoto. 1988. Decrease in BSF-2/IL-6 response in advanced cases of multiple myeloma.. https://pubmed.ncbi.nlm.nih.gov/3261180/
Cite the original work for its findings. Save a collection to share your selection of sources.